



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	72.75
Trade Time:	4:00 PM ET Nov 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	26.54 - 92.18
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Nov 19, 2018*

[Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test](#)

*Nov 8, 2018*

[Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum](#)

*Nov 6, 2018*

[Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance](#)

*Oct 30, 2018*

[Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018](#)

*Oct 29, 2018*

[Medicare Establishes Final Local Coverage Determination \(LCD\) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10](#)

### Financials & Filings [\[ View all \]](#)

*Mar 14, 2018*

[Annual Report \(10-K\)](#)

*Apr 27, 2018*

[Proxy Statement \(DEF 14A\)](#)

*Nov 8, 2018*

[Quarterly Report \(10-Q\)](#)

*Aug 7, 2018*

[Quarterly Report \(10-Q\)](#)

*May 9, 2018*

[Quarterly Report \(10-Q\)](#)